Microdosing Tirzepatide

Explore tirzepatide through an individualized lower-dose strategy.

How it is intended to help: Tirzepatide activates GIP and GLP-1 receptors that influence appetite and food intake. The weight-management product uses a studied titration schedule for eligible patients. Microdosing uses lower or nonstandard doses.

What to expect: Lower dosing may be selected to assess tolerability, but it does not guarantee fewer side effects or reliable weight loss. Nausea, diarrhea, vomiting, constipation, and abdominal discomfort can occur. Screening should address pregnancy, pancreatitis, gallbladder disease, diabetes medicines, kidney risk, severe digestive disease, and medullary thyroid carcinoma or MEN 2 history. Use only the exact syringe units and milligram dose on the pharmacy label